Market Newsdesk

PHILADELPHIA, June 29, 2026 /PRNewswire/ — National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against Zillow Group, Inc. (NASDAQ: ZG, Z) (“Zillow” or the “Company”) on behalf of investors who purchased or acquired Zillow common stock during the period from February 11, 2025 through May 7, 2026 (the “Class Period”).

Investor Deadline:

Investors who purchased or acquired Zillow securities during the Class Period may, no later than

August 10, 2026

, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,


CLICK HERE

.

Based in Seattle, Washington, Zillow operates a network of online rental and housing platforms serving renters, property managers, and multifamily housing operators. The Company generates revenue through rental advertising, lead generation, and other housing-related services.

According to the complaint, throughout the Class Period, Defendants described Zillow’s February 2025 transaction with Redfin as a strategic partnership that would broaden the Company’s rental listings business. The complaint alleges that Defendants failed to disclose that the arrangement effectively transferred Redfin’s multifamily rental advertising operations to Zillow and materially increased the Company’s exposure to antitrust scrutiny.

The truth allegedly began to emerge on September 30, 2025, when the FTC sued Zillow and Redfin, alleging that the companies entered into an unlawful agreement that resulted in Redfin’s exit from the multifamily rental advertising market.

Thereafter, on February 10, 2026, Zillow disclosed that higher-than-expected legal expenses had adversely affected financial results and would continue to pressure profitability in the first quarter of 2026.

The alleged risks were further materialized on May 7, 2026, when a federal court rejected Zillow’s and Redfin’s efforts to dismiss the FTC action. Following each of these revelations, Zillow’s Class A and Class C common declined materially.

If you are a Zillow investor and would like to learn more about this action,



CLICK HERE



or please contact Berger Montague: Andrew Abramowitz at



[email protected]

 or (215) 875-3015, or Caitlin Adorni at [email protected] or (267) 764-4865.

About Berger Montague

Berger Montague is one of the nation’s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:

Andrew Abramowitz
Berger Montague
(215) 875-3015
[email protected]

Caitlin Adorni
Berger Montague
(267) 764-4865
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/attention-nasdaq-zg-investors-contact-berger-montague-about-a-zillow-group-inc-class-action-lawsuit-302812806.html

SOURCE Berger Montague

Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohorts

MENLO PARK, Calif., June 29, 2026 /PRNewswire/ — BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the publication of Longitudinal Methylated ctDNA Increases Predict Immunotherapy Progression Across Solid Tumors, a peer-reviewed study demonstrating that Northstar Response^® was a stronger predictor of survival than standard-of-care imaging in patients with advanced solid tumors receiving immunotherapy or immunotherapy combination therapy, and that the addition of molecular monitoring to imaging provided greater predictive power than imaging alone. The findings were reproduced in an independent prospective validation cohort, with consistent results across tumor types and treatment regimens.

Conducted in collaboration with the Allegheny Health Network Cancer Institute, the study enrolled 142 patients across two independent cohorts spanning 12 solid tumor types. In a multivariate analysis incorporating both Northstar Response and blinded central radiographic review using RECIST criteria, molecular progression emerged as the dominant independent predictor of survival (hazard ratio 5.3), substantially outweighing radiographic progression. The strongest predictive performance came from pairing Northstar Response with imaging: patients whose disease progressed on both molecular and imaging assessment had the poorest outcomes of all (hazard ratio 13.8 at the landmark assessment; 19.7 with continued longitudinal monitoring), and the combined molecular-plus-imaging approach achieved the highest predictive discrimination of any method evaluated.

Northstar Response also helped resolve a particularly challenging clinical dilemma in oncology: patients whose imaging show “stable disease” and thus have findings that cannot reliably be distinguished between early treatment benefit and failure. Among these patients, molecular progression identified those at substantially higher risk and conveyed prognostic information that imaging alone could not provide.

On average, Northstar Response identified cancer progression a median of 62 days before clinicoradiographic progression, representing a potentially actionable window for oncologists to reassess surveillance or treatment strategy before conventional methods signal failure. The assay achieves this through simple serial blood draws collected throughout treatment that integrate into routine oncology practice.

“The lead time advantage here is reflective of real-world patient treatment situations and the rhythm of typical oncology practices — by using Response, a physician has information two treatment cycles earlier than they would when using imaging alone,” said Ali Zaidi, MD, Professor of Surgery and Medicine at Drexel University College of Medicine; Medical Director of Aerodigestive Research at Allegheny Cancer Institute, Allegheny Health Network. “That window has real implications for how we manage patients.”

The study also found that 1 in 4 patients exhibited a molecular rebound pattern (an early favorable decrease signal followed by a subsequent rise) that suggests a single ctDNA assessment could misclassify patients as responding when the likelihood of treatment failure remains high. Only through serial sampling across multiple cycles were the investigators able to fully capture this kinetic shift, underscoring an important limitation of single-timepoint monitoring approaches for patients receiving immunotherapy.

“For patients with advanced cancer on immunotherapy, the clinical question that matters most isn’t whether treatment is working at week four — it’s whether it’s still working over time,” said Dr. Zaidi. “These data show that serial molecular monitoring can answer that question earlier, and more independently, than imaging alone.”

The Northstar Response assay uses proprietary single-molecule next-generation sequencing (smNGS) platform with Quantitative Counting Template^™ (QCT^™) technology to quantify tumor-specific methylation from a simple blood draw, enabling treatment response monitoring across multiple solid tumor types. Northstar Response complements Northstar Select^®, BillionToOne’s liquid biopsy for therapy selection in cancer patients. Together, the assays support clinicians from treatment selection through ongoing response monitoring without dependence on tumor tissue.

“Therapy selection and treatment monitoring are two of the most important decisions in oncology,” said Allen Chen, MD, Vice President of Oncology Clinical Development and Medical Affairs at BillionToOne. “Through simple blood draws, Northstar Select and Northstar Response provide clinicians with complementary molecular tools that allow for truly personalized cancer care to guide patients throughout their treatment journey.”

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company’s patented Quantitative Counting Templates^™ (QCT^™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.

About Northstar Select^®

Northstar Select, BillionToOne’s highly sensitive comprehensive genomic profiling (CGP) liquid biopsy assay, demonstrated superior performance in detecting more clinically actionable alterations in circulating tumor DNA (ctDNA) compared to other liquid biopsy tests on the market. In a prospective head-to-head comparison study which included 182 patients with more than 17 solid tumor types, Northstar Select detected 51% more clinically actionable or pathogenic single nucleotide variant (SNV)/Indels and 109% more copy number variants (CNVs) than the aggregated results from available comparators, with 45% fewer null reports.²

About Northstar Response^®

Northstar Response is BillionToOne’s tissue-free, methylation-based ctDNA assay purpose-built for treatment response monitoring in patients with cancer. Powered by the company’s patented QCT^™ molecular counting platform — the only multiplex technology capable of counting DNA molecules at the single-molecule level — Northstar Response quantifies tumor burden through serial blood draws with no dependence on tumor tissue at any stage of the patient journey.

Disclaimer

Northstar Select and Northstar Response may produce false-positive or false-negative results. Test results are not a guarantee of the presence or absence of disease or treatment response and should not be used as the sole basis for medical decision-making. Results should be interpreted in conjunction with the patient’s clinical presentation, radiographic findings, and other diagnostic information. Northstar Response is intended to complement, not replace, standard clinical and radiographic assessment of disease status. Northstar Select and Northstar Response are laboratory-developed tests (LDTs) performed in a CLIA-certified and CAP-accredited laboratory. These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test performance may vary based on factors including cancer type, disease burden, treatment, and specimen characteristics.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding the clinical performance and utility of Northstar Response. These statements are based on management’s current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, some of which are beyond BillionToOne’s control. These and additional risks and uncertainties could affect BillionToOne’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These risks and uncertainties include, but are not limited to, those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in BillionToOne’s most recently filed Quarterly Report on Form 10-Q, its Annual Report on Form 10-K, and other filings the company makes with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to BillionToOne as of the date hereof, and BillionToOne disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing BillionToOne’s views as of any date subsequent to the date of this press release.

1. Anees et al. Longitudinal Methylated ctDNA Increases Predict Immunotherapy Progression Across Solid Tumors, The Journal of Liquid Biopsy, https://doi.org/10.1016/ j.jlb.2026.100477

2. Bower, X., Wignall, J., Varga, M. G., et al. Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling. The Journal of Liquid Biopsy. https://doi.org/10.1016/j.jlb.2025.100322. Head-to-head improvement % determined when compared to comparator products in the aggregate. Actual percentages may vary depending on the individual comparator liquid biopsy test.

Media Contact

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/billiontoones-northstar-response-is-a-stronger-predictor-of-immunotherapy-outcomes-than-standard-of-care-imaging-for-cancer-patients-in-peer-reviewed-study-302813448.html

SOURCE BillionToOne

NEW YORK, June 29, 2026 /PRNewswire/ — Mitsubishi UFJ Financial Group (MUFG), one of the world’s largest global financial groups, proudly announces a Japanese Operating Lease with Call Option (“JOLCO”) facility for Viva Aerobus (“Viva”), with Three i’s Capital Co., Ltd. (“Three i’s Capital”). The transaction marks Viva’s first JOLCO and Three i’s Capital’s first investment into an aircraft JOLCO.

MUFG acted as the sole Structuring Agent and Lender, and Three i’s Capital acted as Equity Underwriter. The facility supported a May 2026 delivery of an A321neo.

“We are delighted to support Viva on its inaugural JOLCO transaction, a landmark financing that reflects the continued evolution of the airline’s fleet strategy. The transaction demonstrates MUFG’s ability to deliver breakthrough solutions, leveraging our aviation expertise and strong relationships across Japan,” said Aqmar Chowdhury, Deputy Head of Aviation Origination, Americas at MUFG.

“We are pleased to partner with MUFG and Three i’s Capital on Viva’s first JOLCO transaction, an important milestone in the evolution of our fleet financing capabilities. This transaction broadens the array of funding solutions available to support our fleet growth, while further strengthening our relationship with MUFG as we continue executing our long-term fleet strategy,” said Ciprian Rodriguez, Fleet Executive Director at Viva Aerobus.

“This has been a strategically important transaction for us in starting relationships with both Viva and MUFG in a new asset class. We are very pleased with this beginning and look forward to further collaboration with our new partners, as we become a regular participant in aviation leasing,” said Masanori Sueoka

,
Chief Executive Officer
at
Three i’s
Capital
.

About Three i’s Capital Co., Ltd.

Founded in 2014, Three i’s Capital Co., Ltd. is an asset management company headquartered in Tokyo, Japan. The corporate philosophy is embodied in the three “i”s of “intelligence,” “investment,” and “I” in the first person, with the highest integrity to be the perceptive “third eye” for our clients. The core focus is on shipping and aviation leasing and Japanese real estate, while also engaging in principal investments in the real estate, energy, and corporate markets. Three i’s continuously strives to serve investor needs. To get in touch, please visit https://3-iz.com/en/home-en/.

About Viva Aerobus

Viva is a Mexican ultra-low-cost airline that provides air transport services across Mexico, the United States, and other Latin American countries. Founded in 2006, Viva operates one of the youngest aircraft fleets in the Americas. With a clear vision to give all people the opportunity to fly, Viva is focused on democratizing air travel by offering low fares and a low-cost service. For more information, please visit: https://www.vivaaerobus.com/en-us/

About MUFG and MUFG Americas

Mitsubishi UFJ Financial Group, Inc. (MUFG) is one of the world’s leading financial groups. Headquartered in Tokyo and with over 360 years of history, MUFG has a global network with approximately 2,000 locations in more than 40 countries. The Group has about 150,000 employees and offers services including commercial banking, trust banking, securities, credit cards, consumer finance, asset management, and leasing. The Group aims to “be the world’s most trusted financial group” through close collaboration among our operating companies and flexible response to all of the financial needs of our customers, serving society, and fostering shared and sustainable growth for a better world. MUFG’s shares trade on the Tokyo, Nagoya, and New York stock exchanges. For more information, visit https://www.mufg.jp/english.

MUFG’s Americas operations, including its offices in the U.S., Latin America, and Canada, are primarily organized under MUFG Bank, Ltd. and subsidiaries, and are focused on Global Corporate and Investment Banking, Japanese Corporate Banking, and Global Markets. MUFG is one of the largest internationally-headquartered financial institutions in the Americas. For locations, banking capabilities and services, career opportunities, and more, visit https://www.mufgamericas.com/.

Media Contact:
MUFG Media Relations
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/mufg-leads-viva-aerobuss-debut-jolco-302813422.html

SOURCE MUFG Bank, Ltd.

United will be the first U.S. airline to offer nonstop flights from Houston (IAH) and Washington Dulles (IAD) to Cartagena when flights start on December 17

Flights will operate year-round from both hubs, starting with four flights per week

United currently offers service to Bogota and Medellín, Colombia and served the country for more than 30 years

CHICAGO, June 29, 2026 /PRNewswire/ — United today announced it will launch new nonstop service from Houston Intercontinental Airport (IAH) and Washington Dulles International Airport (IAD) to Cartagena, Colombia (CTG) starting December 17.* These new flights will operate year-round from both hubs, starting with four flights per week during the winter season. United will fly a Boeing 737 on this route, and customers on board can enjoy seatback screens at every seat with Bluetooth connectivity, larger overhead bins with room for everyone’s roll aboard bag and soon free Starlink Wi-Fi for MileagePlus members. Lonely Planet named Cartagena as a 2026 Best in Travel destination, noting its well-preserved Spanish architecture, vibrant culinary scene and rich history. Flights are available for sale on United.com and the United app.

“Colombia has been an important part of United’s Latin America network for more than 30 years, and our new service to Cartagena reflects our continued investment in the country and commitment to offering customers new and distinct travel experiences,” said Patrick Quayle, Senior Vice President of Network Planning and Global Alliances, United Airlines. “As our third destination in Colombia, complementing our service to Bogota and Medellín, Cartagena gives our customers access to a different side of the country while making it easier for travelers across North America to experience one of the Caribbean’s most iconic destinations.”

“The architectural beauty, vibrant culture and thriving culinary scene are just a few reasons why travel experts say Cartagena should be on people’s bucket list this year,” said David Kinzelman, Senior Vice President and Chief Customer Officer at United Airlines. “By flying direct, we’ll give our customers even more time to see the sights and along the way, they’ll enjoy all the value we pack into each flight – seatback screens, Bluetooth connections, larger overhead bins and a suite of tools to make the journey easier in the United app.”

United offers more flights to Latin America than any other airline in both Texas and the Washington, D.C. area, offering nonstop flights to 57 destinations from its hub in Houston and 18 from Dulles. The new routes will connect Cartagena to more than 70 destinations across the U.S. from United’s hubs in Houston and Washington, D.C.   

Schedule Details

About United

At United, Good Leads The Way. With U.S. hubs in Chicago, Denver, Houston, Los Angeles, New York/Newark, San Francisco and Washington, D.C., United operates the most comprehensive global route network among North American carriers, and is now the largest airline in the world as measured by available seat miles. For more about how to join the United team, please visit www.united.com/careers and more information about the company is at www.united.com. United Airlines Holdings, Inc., the parent company of United Airlines, Inc., is traded on the Nasdaq under the symbol “UAL”.

View original content to download multimedia:https://www.prnewswire.com/news-releases/united-announces-new-nonstop-flights-from-houston-and-washington-dc-to-cartagena-302813361.html

SOURCE United Airlines

Nearly 1,700 runners from 44 states and seven countries — ages 14 to 80 — take on America’s toughest marathon and its 13,185-foot Mosquito Pass summit

LEADVILLE, Colo., June 29, 2026 /PRNewswire/ — Life Time (NYSE: LTH), the nation’s premier healthy lifestyle brand and producer of nearly 30 iconic athletic events, welcomed nearly 1,700 runners to Leadville, Colorado this weekend for the sold-out Life Time Leadville Trail Marathon & Heavy Half presented by La Sportiva.

Representing 44 states and seven countries, athletes ranging in age from 14 to 80 gathered in the highest incorporated city in the United States to test themselves against one of endurance running’s most demanding challenges. The event also marked the official start of the 2026 Life Time Leadville Race Series season, kicking off five weekends of trail running and mountain biking events throughout the summer.

Among the participants were 119 athletes taking on the coveted Lead Challenge, one of endurance sport’s most demanding season-long achievements. To earn the Lead Challenge buckle, athletes must complete five Leadville Race Series events throughout the summer, culminating with both the Life Time Leadville Trail 100 MTB and Life Time Leadville Trail 100 Run. Their journey began Saturday on the slopes of Mosquito Pass and will continue across the iconic Leadville Race Series season.

Known as the nation’s toughest marathon, the Leadville Trail Marathon sends runners across historic mining roads and rugged mountain trails before summiting Mosquito Pass at 13,185 feet above sea level — the highest point in the Leadville Race Series and one of the highest continuous mountain passes in North America. Marathon participants conquered more than 6,000 feet of elevation gain, while Heavy Half runners tackled 15.4 miles and more than 3,400 feet of climbing on their journey to the same alpine summit.

Full race results are available here.

“As we celebrate 25 years of owning and producing athletic events, the Leadville Trail Marathon and Heavy Half embody everything that makes endurance sports so powerful,” said Kimo Seymour, Senior Vice President of Events at Life Time. “Colorado has long been one of the epicenters of endurance culture, and Leadville sits at the heart of that legacy. As Life Time continues to grow our presence across Colorado, we’re proud to create experiences that connect our members, athletes and communities through challenge, adventure and personal transformation.”

Beyond the competition, the marathon also serves as a qualifier for the Life Time Leadville Trail 100 Run presented by La Sportiva. Top finishers and lottery recipients earned coveted qualifier coins, bringing them one step closer to competing in the world-renowned 100-mile ultramarathon later this summer.

The Leadville Trail Marathon & Heavy Half serves as the opening chapter of the 2026 Leadville Race Series, which includes the Silver Rush 50 Run and MTB, Leadville Stage Race, Leadville Trail 100 MTB and Leadville Trail 100 Run. Together, the series represents one of the most storied endurance journeys in sport, challenging athletes to push beyond perceived limits while fostering a community built on grit, determination and camaraderie.

The Leadville Race Series is part of Life Time’s portfolio of nearly 30 premier athletic events, which includes UNBOUND Gravel, the Sea Otter Classic, Big Sugar Gravel, the Miami Marathon and other iconic experiences across the country. As Life Time celebrates 25 years of producing athletic events, the company continues to create opportunities for athletes of all abilities to pursue ambitious goals, connect through community and experience transformative moments in some of the world’s most inspiring destinations.

For more information on the Leadville Race Series, visit leadvilleraceseries.com.

About Life Time

Life Time (NYSE: LTH) empowers people to live healthy, happy lives through its more than 190 athletic country clubs across the U.S. and Canada, the complimentary and comprehensive Life Time app featuring its L•AI•C™ AI-powered health companion, and more than 30 iconic athletic events. Serving people ages 90 days to 90+ years, the Life Time ecosystem uniquely delivers healthy living, healthy aging, and healthy entertainment experiences, a range of unique healthy way of life programs, highly trusted LTH nutritional supplements and more. Recognized as a Great Place to Work^®, the company is committed to upholding an exceptional culture for its more than 50,000 team members.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sold-out-life-time-leadville-trail-marathon–heavy-half-presented-by-la-sportiva-kicks-off-2026-leadville-race-series-season-302813378.html

SOURCE Life Time, Inc.

AUSTIN, Minn., June 29, 2026 /PRNewswire/ — Hormel Foods Corporation (NYSE: HRL), a Fortune 500 global branded food company, today announced it has entered into a definitive agreement to sell its Brazilian operations, operated under the CERATTI^® brand to Zanchetta Alimentos LTDA, a Brazilian food company with an established presence in the market.

The divestiture reflects Hormel Foods ongoing efforts to simplify and streamline its portfolio and focus its international strategy on markets with the strongest long-term growth opportunities.

The transaction is expected to close in the coming weeks, subject to customary closing conditions, including required regulatory approval. In the interim, operations will continue as usual for employees, customers and partners.

Financial details of the transaction have not been disclosed. Hormel Foods expects the sale to have a minimal impact on its adjusted fiscal 2026 financial results. The company expects to share additional information during its earnings call for the third quarter of fiscal 2026. 

About Hormel Foods
Hormel Foods Corporation, based in Austin, Minnesota, is a global branded food company with over $12 billion in annual revenue. Its brands include PLANTERS®, SKIPPY®, SPAM®, HORMEL® NATURAL CHOICE®, APPLEGATE®, WHOLLY®, HORMEL® BLACK LABEL®, COLUMBUS®, JENNIE-O® and more than 30 other beloved brands. The Company is a member of the S&P 500 Index and the S&P 500 Dividend Aristocrats, was named one of the best companies to work for by U.S. News & World Report and one of America’s most responsible companies by Newsweek, was recognized by TIME magazine as one of the World’s Best Companies and has received numerous other awards and accolades for its corporate responsibility and community service efforts. For more information, visit hormelfoods.com.

FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements, which are based on the current assumptions and expectations of Hormel Foods Corporation (“Hormel”). These statements are typically accompanied by the words “expect,” “will,” “would,” or similar words or expressions. The principal forward-looking statements in this news release include statements regarding Hormel’s anticipated sale of its Ceratti business in Brazil, international growth opportunities, and the expected impact of the transaction on Hormel’s fiscal 2026 financial results.

All such forward-looking statements are intended to enjoy the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, as amended. Although Hormel believes there is a reasonable basis for the forward-looking statements, its actual results could be materially different. The most important factors which could cause Hormel’s actual results to differ from its forward-looking statements include, but are not limited to, risks related to the deterioration of economic conditions; risks related to acquisitions, joint ventures, equity investments, and divestitures; risks and uncertainties associated with intangible assets, including any future goodwill or intangible assets impairment charges; the risk of disruption of operations; the risk that Hormel may fail to realize anticipated cost savings or operating profit improvements associated with strategic initiatives, including the Transform and Modernize initiative and Hormel’s recent corporate restructuring plan; risk of unfavorable changes in Hormel’s relationships with third parties; risk of Hormel’s inability to protect information technology (IT) systems against, or effectively respond to, cyber-attacks, security breaches or other IT interruptions; labor relations and labor availability risks; food safety risks; fluctuations in commodity prices and availability of raw materials and other inputs; fluctuations in market demand for Hormel’s products; risks related to Hormel’s ability to respond to changing consumer preferences; damage to Hormel’s reputation or brand image; risks of litigation; risks associated with government regulation; risks related to trade policies, export and import controls, and tariffs; and the other risks and uncertainties described in Item 1A – Risk Factors of Hormel’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which can be accessed at www.hormelfoods.com in the “Investors” section. Though Hormel has attempted to list comprehensively these important cautionary risk factors, Hormel cautions that other factors may in the future prove to be important in affecting Hormel’s business or results of operations. Forward-looking statements speak only as of the date they are made, and Hormel does not undertake any obligation to update any forward-looking statement except as otherwise required by law.

Contact:        
Media Relations        
Hormel Foods
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/hormel-foods-announces-agreement-to-sell-ceratti-business-in-brazil-302813370.html

SOURCE Hormel Foods Corporation

ZURICH, June 29, 2026 /PRNewswire/ — Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, today announced a collaboration with U.K.-based startup Kelpi to explore next-generation coating technologies designed to enhance the performance and sustainability of packaging materials.

The partnership with Kelpi supports Amcor’s broader innovation strategy focused on identifying and advancing solutions that enable more sustainable packaging while maintaining high functional standards. Amcor’s research and development teams are currently evaluating Kelpi’s proprietary coating technology platform, a bio-based¹ seaweed material designed to deliver barrier performance and compatibility with recycling streams for fiber-based packaging.

By evaluating breakthrough bio-based coating technologies, Amcor aims to further expand the options within its AmFiber™ fiber-based solutions platform to continue meeting demanding application requirements such as barrier performance, high running speed and circularity. The potential benefits of using such bio-based coatings include reduced reliance on fossil fuel-derived feedstocks and greater use of renewable resources, which may contribute to a lower carbon footprint.

“This collaboration reflects how we are advancing our material innovation pipeline, and it supports the Ellen MacArthur Foundation’s call for accelerated innovation in paper-based flexible packaging²,” said Peter Ettridge, Director, Research and Development, AmFiber™, Amcor. “We’re excited by the potential of Kelpi’s technology, which combines processability, gas and moisture barrier performance, and paper recyclability.”

“Partnering with companies like Kelpi is a key part of how we bring new technologies into our innovation ecosystem,” said Frank Lehmann, Vice President, Corporate Venturing and Open Innovation, Amcor. “Its innovative approach to leveraging nature-sourced materials that won’t compromise packaging performance is promising, and we’re excited to explore opportunities to scale the technology within our global packaging portfolio.”

By combining Kelpi’s technology with Amcor’s global research and development capabilities and scale, the companies aim to evaluate commercially viable, scalable solutions for customers across various consumer goods sectors, supporting a circular economy for packaging.

Learn more about corporate venturing at Amcor.

About Amcor

Amcor is the global leader in developing and producing responsible consumer packaging and dispensing solutions across a variety of materials for nutrition, health, beauty and wellness categories. Our global product innovation and sustainability expertise enables us to solve packaging challenges around the world every day, producing a range of flexible packaging, rigid packaging, cartons and closures that are more sustainable, functional and appealing for our customers and their consumers. We are guided by our purpose of elevating customers, shaping lives and protecting the future. Supported by a commitment to safety, over 75,000 people generate $23 billion in annualized sales from operations that span over 400 locations in more than 40 countries. NYSE: AMCR; ASX: AMC

www.amcor.com | LinkedIn | YouTube 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amcor-partners-with-kelpi-to-advance-next-generation-barrier-materials-for-fiber-packaging-302813363.html

SOURCE Amcor